Should I buy or sell Syros Pharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SYRS shares. View SYRS analyst ratings or view top-rated stocks .

What is Syros Pharmaceuticals' stock price target for 2024?

3 brokers have issued 12-month target prices for Syros Pharmaceuticals' stock. Their SYRS share price targets range from $7.00 to $15.00. On average, they anticipate the company's share price to reach $12.50 in the next twelve months. This suggests a possible upside of 60.5% from the stock's current price. View analysts price targets for SYRS or view top-rated stocks among Wall Street analysts .

How have SYRS shares performed in 2023?

Syros Pharmaceuticals' stock was trading at $3.59 at the beginning of 2023. Since then, SYRS stock has increased by 117.0% and is now trading at $7.79. View the best growth stocks for 2023 here .

When is Syros Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024. View our SYRS earnings forecast .

How were Syros Pharmaceuticals' earnings last quarter?

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) announced its earnings results on Tuesday, November, 14th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by $0.23. The company earned $3.76 million during the quarter, compared to the consensus estimate of $3.90 million.

When did Syros Pharmaceuticals' stock split?

Shares of Syros Pharmaceuticals reverse split on Monday, September 19th 2022. The 1-10 reverse split was announced on Monday, September 19th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Nancy Simonian's approval rating as Syros Pharmaceuticals' CEO?

3 employees have rated Syros Pharmaceuticals Chief Executive Officer Nancy Simonian on Glassdoor.com . Nancy Simonian has an approval rating of 100% among the company's employees. This puts Nancy Simonian in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Syros Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP) , Sangamo Therapeutics (SGMO) , Advanced Micro Devices (AMD) , CRISPR Therapeutics (CRSP) , ImmunoGen (IMGN) , VBI Vaccines (VBIV) , Amarin (AMRN) , Amicus Therapeutics (FOLD) , Nektar Therapeutics (NKTR) and Pfizer (PFE) .

When did Syros Pharmaceuticals IPO?

(SYRS) raised $60 million in an IPO on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

How do I buy shares of Syros Pharmaceuticals?

Shares of SYRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:SYRS

Syros Pharmaceuticals (SYRS) Stock Price, News & Analysis

$7.79

+0.59 (+8.19%)

(As of 12/29/2023 ET)

Compare

Today's Range: $7.02
▼
$8.05
50-Day Range: $2.19
▼
$7.79
52-Week Range: $2.09
▼
$8.05

Volume: 502,210 shs
Average Volume: 534,253 shs
Market Capitalization: $164.14 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.50

Syros Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 60.5% Upside
$12.50 Price Target
Short Interest: Healthy
2.46% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.57
Upright™ Environmental Score
News Sentiment: 1.16
Based on 5 Articles This Week
Insider Trading: Acquiring Shares
$4 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($4.73) to ($3.75) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.65 out of 5 stars

Medical Sector

82nd out of 950 stocks

Pharmaceutical Preparations Industry

29th out of 442 stocks

3.5

Analyst's Opinion

Consensus Rating
Syros Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $12.50, Syros Pharmaceuticals has a forecasted upside of 60.5% from its current price of $7.79.
Amount of Analyst Coverage
Syros Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.46% of the float of Syros Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Syros Pharmaceuticals has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Syros Pharmaceuticals has recently increased by 2.05%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Syros Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Syros Pharmaceuticals does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Syros Pharmaceuticals has received a 68.11% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" product. See details.
Environmental Sustainability
The Environmental Impact score for Syros Pharmaceuticals is -0.57.

4.0

News and Social Media Coverage

News Sentiment
Syros Pharmaceuticals has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Syros Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
16 people have searched for SYRS on MarketBeat in the last 30 days. This is an increase of 129% compared to the previous 30 days.
MarketBeat Follows
2 people have added Syros Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Syros Pharmaceuticals insiders have bought 16,006.94% more of their company's stock than they have sold. Specifically, they have bought $3,999,998.00 in company stock and sold $24,834.00 in company stock.
Percentage Held by Insiders
10.45% of the stock of Syros Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
51.29% of the stock of Syros Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Syros Pharmaceuticals are expected to grow in the coming year, from ($4.73) to ($3.75) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Syros Pharmaceuticals is -2.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Syros Pharmaceuticals is -2.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Syros Pharmaceuticals has a P/B Ratio of 1.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Syros Pharmaceuticals Stock (NASDAQ:SYRS)

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

SYRS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SYRS Stock News Headlines

December 27, 2023 | americanbankingnews.com

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Director Srinivas Akkaraju Purchases 904,977 Shares

December 26, 2023 | markets.businessinsider.com

These Biotech Stocks Climbed To New Peaks - Did You Invest?

December 31, 2023 | MarketBeat Internal (Ad)

New Year's Sale: Get MarketBeat All Access Free For 30 Days

Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Click the link to claim your $300.00 account credit and free 30-day subscription

December 19, 2023 | seekingalpha.com

Syros prices capital raise of $45.0 million via securities offering

December 19, 2023 | finance.yahoo.com

Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants

December 13, 2023 | finance.yahoo.com

individual investors who own 35% along with institutions invested in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) saw increase in their holdings value last week

December 7, 2023 | markets.businessinsider.com

Buy Rating Justified by Syros Pharmaceuticals’ Strong Clinical Results and Market Potential

December 6, 2023 | msn.com

Why Is Blood Cancer Focused Syros Pharmaceuticals Stock Soaring Today?

December 31, 2023 | MarketBeat Internal (Ad)

Claim Your $300 MarketBeat Account Credit

Click the link below to claim your $300.00 account credit toward MarketBeat All Access. Pay just $99.00 for your 2024 MarketBeat All Access subscription (normally $399.00)

December 6, 2023 | msn.com

Syros jumps after Phase 2 data for leukemia therapy

December 6, 2023 | markets.businessinsider.com

Syros Presents Positive Phase 2 Trial Data Of Tamibarotene Combination: Stock Up In Premarket

December 6, 2023 | finance.yahoo.com

Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine

November 16, 2023 | markets.businessinsider.com

Piper Sandler Keeps Their Buy Rating on Syros Pharmaceuticals (SYRS)

November 15, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Syros Pharmaceuticals (SYRS) and Kiora Pharmaceuticals (KPRX)

November 15, 2023 | finance.yahoo.com

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2023 Earnings Call Transcript

November 14, 2023 | markets.businessinsider.com

Syros Pharmaceuticals Q3 Loss misses estimates

November 14, 2023 | finance.yahoo.com

Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

November 13, 2023 | benzinga.com

Preview: Syros Pharmaceuticals's Earnings

November 12, 2023 | morningstar.com

Syros Pharmaceuticals Inc SYRS

November 7, 2023 | finance.yahoo.com

Syros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023

October 4, 2023 | bizjournals.com

Syros CEO, chief scientist out as company cuts staff, programs

October 3, 2023 | marketwatch.com

Syros Pharmaceuticals Shares Fall 18% on Staff Cuts, CEO Retirement

October 2, 2023 | marketwatch.com

Syros Pharmaceuticals to Cut 35% of Staff; CEO Simonian to Retire

October 2, 2023 | finance.yahoo.com

Syros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical Company

August 10, 2023 | markets.businessinsider.com

Piper Sandler Reaffirms Their Buy Rating on Syros Pharmaceuticals (SYRS)

August 9, 2023 | markets.businessinsider.com

Syros Pharmaceuticals (SYRS) Gets a Buy from H.C. Wainwright

August 9, 2023 | finance.yahoo.com

Q2 2023 Syros Pharmaceuticals Inc Earnings Call

See More Headlines

Receive SYRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2023
Today: 12/31/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/07/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SYRS
CUSIP: N/A
CIK: 1556263
Web: www.syros.com
Phone: (617) 744-1340
Fax: N/A
Employees: 117
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $12.50
High Stock Price Target: $15.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +60.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.75)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-94,650,000.00
Net Margins: N/A
Pretax Margin: -1,193.45%
Return on Equity: -155.06%
Return on Assets: -68.52%

Debt

Debt-to-Equity Ratio: 1.09
Current Ratio: 4.31
Quick Ratio: 4.31

Sales & Book Value

Annual Sales: $14.88 million
Price / Sales: 11.03
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.32 per share
Price / Book: 1.23

Miscellaneous

Outstanding Shares: 21,070,000
Free Float: 18,865,000
Market Cap: $164.14 million
Optionable: Optionable
Beta: 1.46

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Dr. Richard A. Young Ph.D. (Age 69)
Scientific Founder, Member of Scientific Advisory Board & Director
Comp: $108.37k
Dr. David A. Roth M.D. (Age 60)
Chief Medical Officer
Comp: $679.52k
Mr. Conley Chee (Age 53)
CEO, President & Director
Dr. James E. Bradner M.D. (Age 51)
Founder
Dr. Nathanael S. Gray Ph.D.
Scientific Founder & Member of Scientific Advisory Board
Mr. Jason Haas (Age 55)
Chief Financial Officer
Comp: $457.22k
Ms. Karen Hunady M.S.
Director of Corporate Communications & Investor Relations
Mr. Gerald E. Quirk Esq. (Age 55)
J.D., Chief Legal & Compliance Officer
Comp: $127.07k
Ms. Lisa Roberts
Vice President of Human Resources
Ms. Kristin Stephens (Age 50)
Chief Development Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SYRS Stock Analysis - Frequently Asked Questions

Should I buy or sell Syros Pharmaceuticals stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SYRS shares.
View SYRS analyst ratings or view top-rated stocks.
What is Syros Pharmaceuticals' stock price target for 2024?: 3 brokers have issued 12-month target prices for Syros Pharmaceuticals' stock. Their SYRS share price targets range from $7.00 to $15.00. On average, they anticipate the company's share price to reach $12.50 in the next twelve months. This suggests a possible upside of 60.5% from the stock's current price.
View analysts price targets for SYRS or view top-rated stocks among Wall Street analysts.
How have SYRS shares performed in 2023?: Syros Pharmaceuticals' stock was trading at $3.59 at the beginning of 2023. Since then, SYRS stock has increased by 117.0% and is now trading at $7.79.
View the best growth stocks for 2023 here.
When is Syros Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024.
View our SYRS earnings forecast.
How were Syros Pharmaceuticals' earnings last quarter?: Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) announced its earnings results on Tuesday, November, 14th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by $0.23. The company earned $3.76 million during the quarter, compared to the consensus estimate of $3.90 million.
When did Syros Pharmaceuticals' stock split?: Shares of Syros Pharmaceuticals reverse split on Monday, September 19th 2022. The 1-10 reverse split was announced on Monday, September 19th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Nancy Simonian's approval rating as Syros Pharmaceuticals' CEO?: 3 employees have rated Syros Pharmaceuticals Chief Executive Officer Nancy Simonian on Glassdoor.com. Nancy Simonian has an approval rating of 100% among the company's employees. This puts Nancy Simonian in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Syros Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunoGen (IMGN), VBI Vaccines (VBIV), Amarin (AMRN), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Pfizer (PFE).
When did Syros Pharmaceuticals IPO?: (SYRS) raised $60 million in an IPO on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
How do I buy shares of Syros Pharmaceuticals?: Shares of SYRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SYRS) was last updated on 12/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial